Phreesia, Inc.

DB:19P Stock Report

Market Cap: €1.1b

Phreesia Valuation

Is 19P undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 19P when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 19P (€18.1) is trading below our estimate of fair value (€103.13)

Significantly Below Fair Value: 19P is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 19P?

Key metric: As 19P is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 19P. This is calculated by dividing 19P's market cap by their current revenue.
What is 19P's PS Ratio?
PS Ratio2.9x
SalesUS$389.96m
Market CapUS$1.15b

Price to Sales Ratio vs Peers

How does 19P's PS Ratio compare to its peers?

The above table shows the PS ratio for 19P vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.1x
NXU Nexus
4.5x9.8%€1.2b
COP CompuGroup Medical SE KGaA
0.6x1.4%€726.9m
M3V MeVis Medical Solutions
2.6xn/a€45.1m
AJ91 DocCheck
0.8xn/a€42.1m
19P Phreesia
2.9x11.9%€1.1b

Price-To-Sales vs Peers: 19P is expensive based on its Price-To-Sales Ratio (2.9x) compared to the peer average (2.1x).

Price to Sales Ratio vs Industry

How does 19P's PS Ratio compare vs other companies in the European Healthcare Services Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
19P 2.9xIndustry Avg. 2.2xNo. of Companies11PS02.44.87.29.612+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 19P is expensive based on its Price-To-Sales Ratio (2.9x) compared to the European Healthcare Services industry average (2.2x).

Price to Sales Ratio vs Fair Ratio

What is 19P's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

19P PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.9x
Fair PS Ratio2.9x

Price-To-Sales vs Fair Ratio: 19P is expensive based on its Price-To-Sales Ratio (2.9x) compared to the estimated Fair Price-To-Sales Ratio (2.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 19P forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€18.10
€27.00
+49.2%
9.8%€31.30€21.17n/a15
Nov ’25€16.70
€27.00
+61.7%
9.8%€31.30€21.17n/a15
Oct ’25€20.40
€26.55
+30.2%
9.5%€30.80€20.84n/a16
Sep ’25€22.80
€26.72
+17.2%
8.6%€31.40€21.24n/a16
Aug ’25€23.00
€26.72
+16.2%
8.6%€31.40€21.24n/a16
Jul ’25€19.50
€26.69
+36.9%
8.0%€31.22€21.12n/a16
Jun ’25€19.50
€27.42
+40.6%
9.2%€32.26€21.20n/a16
May ’25€19.30
€27.81
+44.1%
9.9%€34.16€21.24n/a16
Apr ’25€22.40
€27.81
+24.2%
9.9%€34.16€21.24n/a16
Mar ’25€22.80
€26.15
+14.7%
16.0%€33.18€15.67n/a16
Feb ’25€23.60
€25.34
+7.4%
15.3%€33.13€15.64n/a15
Jan ’25€21.20
€24.99
+17.9%
15.5%€32.98€15.57n/a14
Dec ’24€14.00
€33.78
+141.3%
12.2%€40.27€27.16n/a14
Nov ’24€12.90
€33.78
+161.8%
12.2%€40.27€27.16€16.7014
Oct ’24€17.50
€33.78
+93.0%
12.2%€40.27€27.16€20.4014
Sep ’24€26.20
€35.72
+36.3%
9.2%€42.13€27.47€22.8015
Aug ’24€28.80
€35.72
+24.0%
9.2%€42.13€27.47€23.0015
Jul ’24€27.40
€35.72
+30.4%
9.2%€42.13€27.47€19.5015
Jun ’24€28.00
€36.25
+29.5%
9.2%€42.75€27.88€19.5015
May ’24€28.40
€36.11
+27.1%
9.9%€42.15€27.49€19.3015
Apr ’24€28.13
€36.50
+29.8%
10.1%€42.44€27.68€22.4014
Mar ’24€34.57
€35.86
+3.7%
15.5%€43.54€24.08€22.8014
Feb ’24€34.18
€34.56
+1.1%
14.0%€42.32€23.92€23.6014
Jan ’24€30.85
€33.43
+8.4%
11.9%€38.38€24.34€21.2014
Dec ’23€26.50
€33.35
+25.8%
15.0%€41.22€22.67€14.0014
Nov ’23€27.62
€33.35
+20.7%
15.0%€41.22€22.67€12.9014

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-5.5%

1Y

18.9%

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-8.8%

1Y

-37.3%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%